Stay updated on Daratumumab in Waldenström Macroglobulinemia Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page.

Latest updates to the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page
- Check6 days agoChange DetectedThe page shows a revision tag that updates the version from v3.5.2 to v3.5.3, representing a minor update to the page; the core study details and layout remain the same.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 on the page.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedWaldenström macroglobulinemia is now listed as a condition on the page, and a Resources section has been added with a link to the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check49 days agoChange DetectedRevision: v3.5.0 added and v3.4.3 removed; this appears to be a backend/UI update with no visible changes to the study details.SummaryDifference0.1%

- Check56 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check84 days agoChange DetectedRevision: v3.4.2 was added. The lapse-in-funding notice and the earlier Revision: v3.4.1 entry were removed from the page.SummaryDifference0.4%

Stay in the know with updates to Daratumumab in Waldenström Macroglobulinemia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page.